First Hawaiian Bank Has $2.46 Million Stake in Iqvia Holdings Inc (IQV)

First Hawaiian Bank grew its position in Iqvia Holdings Inc (NYSE:IQV) by 65.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,100 shares of the medical research company’s stock after purchasing an additional 6,746 shares during the period. First Hawaiian Bank’s holdings in Iqvia were worth $2,460,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. CENTRAL TRUST Co raised its stake in Iqvia by 1,150.0% in the fourth quarter. CENTRAL TRUST Co now owns 375 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 345 shares in the last quarter. Berman Capital Advisors LLC purchased a new position in shares of Iqvia during the fourth quarter worth approximately $46,000. ERTS Wealth Advisors LLC purchased a new position in shares of Iqvia during the fourth quarter worth approximately $46,000. Kaizen Advisory LLC raised its stake in shares of Iqvia by 33.1% during the fourth quarter. Kaizen Advisory LLC now owns 450 shares of the medical research company’s stock worth $52,000 after acquiring an additional 112 shares in the last quarter. Finally, Financial Gravity Companies Inc. purchased a new position in shares of Iqvia during the fourth quarter worth approximately $59,000. Institutional investors own 91.01% of the company’s stock.

IQV stock traded down $2.58 during midday trading on Wednesday, reaching $133.71. The company’s stock had a trading volume of 743,585 shares, compared to its average volume of 1,122,914. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 1.57. Iqvia Holdings Inc has a 1 year low of $91.57 and a 1 year high of $146.10. The firm has a market cap of $26.96 billion, a price-to-earnings ratio of 26.12, a PEG ratio of 1.72 and a beta of 0.85.

Iqvia (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 14th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.03. Iqvia had a return on equity of 14.25% and a net margin of 2.49%. The business had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.62 billion. During the same quarter in the prior year, the company earned $1.40 EPS. The business’s revenue was up 6.6% compared to the same quarter last year. Research analysts expect that Iqvia Holdings Inc will post 5.87 EPS for the current year.

Several research analysts have commented on the stock. Wolfe Research assumed coverage on shares of Iqvia in a research note on Tuesday, April 2nd. They set a “market perform” rating on the stock. Barclays lifted their target price on shares of Iqvia from $160.00 to $167.00 and gave the stock an “overweight” rating in a research note on Monday, March 18th. Argus lifted their price target on shares of Iqvia from $140.00 to $160.00 and gave the company a “buy” rating in a report on Monday, February 25th. They noted that the move was a valuation call. Wells Fargo & Co lifted their price target on shares of Iqvia from $140.00 to $160.00 and gave the company an “outperform” rating in a report on Tuesday, February 19th. Finally, UBS Group set a $170.00 price target on shares of Iqvia and gave the company a “buy” rating in a report on Friday, February 15th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $146.88.

In other Iqvia news, insider W Richard Staub sold 27,025 shares of the firm’s stock in a transaction dated Wednesday, February 20th. The stock was sold at an average price of $140.54, for a total value of $3,798,093.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael J. Evanisko sold 1,193 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $144.95, for a total value of $172,925.35. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,172,538 shares of company stock worth $587,465,163. 6.00% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “First Hawaiian Bank Has $2.46 Million Stake in Iqvia Holdings Inc (IQV)” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/17/first-hawaiian-bank-raises-position-in-iqvia-holdings-inc-iqv.html.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: Are analyst ratings accurate?

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.